[37], with permission from Elsevier
Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery
As patients lose substantial weight, their metabolic demands change, potentially altering the dose of levothyroxine needed to maintain euthyroid status
If the drugs are directly both improving weight reduction and cancer reduction, then we need to double down. Ganta wonders the same thing about the drugs apparent positive effects on several conditions, from dementia to sleep apnea: Is it that obesity is causing or contributing to the problem [and that weight loss is causing the improvement], or is the medication directly having an impact through a different mechanism? She hopes there will be more research to parse this out in the years to come
Bacteriostatic water contains a small amount of benzyl alcohol that inhibits bacterial growth, which lets a reconstituted vial be used over multiple weeks when stored properly in a refrigerator
Patients who plateau on semaglutide sometimes see renewed progress after moving to tirzepatide
